As part of an effort to increase its cell therapy manufacturing, Iovance Biotherapeutics is planning to add hundreds of new jobs at its manufacturing site ...

Iovance wants to more than double its manufacturing capacity at the Navy Yard in South Philadelphia. Iovance Biotherapeutics plans to add hundreds of new jobs at the Navy Yard in South ...

Iovance Biotherapeutics' stock has plummeted 90% since my 2020 "Buy" call, despite securing historic approval for its solid tumor cell therapy, Amtagvi because of delays, safety concerns, and high ...

Iovance Biotherapeutics experienced a 10% decline over the last week, amid market turbulence driven by escalating trade tensions and significant losses across major indexes. As broader market ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Iovance reported Q4'24 revenues of $25M from Proleukin, a 51% increase from the prior quarter, but Amtagvi revenues of 48.7M, were up just 16% from the prior quarter. Proleukin revenues could be a ...

When a stock is in a freefall, there's usually a justifiable reason for the decline. But for investors with a high risk tolerance, it could make for a potentially attractive contrarian play.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.